On February 13, 2026, the Hang Seng Indexes Company announced the results of its quarterly review of the Hang Seng Index Series, based on data as of December 31, 2025. CF PHARMTECH (02652) was successfully added to the list of constituents for the Hang Seng Composite Index. The related adjustments will be implemented after the market close on Friday, March 6, 2026, and will take effect formally on Monday, March 9, 2026.

The inclusion in the Hang Seng Composite Index signifies that the company has met a series of criteria, including market capitalization, liquidity, and listing history. This reflects the capital market's strong recognition of the company's sustainable innovation potential and investment value within the specialized inhaled formulation sector.

As an innovator in global inhaled drug delivery technology, CF PHARMTECH is dedicated to building an interdisciplinary bridge connecting complex formulations with unmet clinical needs. The company focuses on developing high-barrier, complex inhaled preparations and operates as a platform-based innovative pharmaceutical company integrating device engineering, precision drug delivery, global regulatory registration, and commercial implementation.

Leveraging its fully self-established global, integrated industrial chain capabilities—ranging from breath-actuated nasal spray delivery systems and liposomal inhalation technology to siRNA nucleic acid delivery platforms—the company is systematically advancing an innovative pipeline targeting markets in China, the United States, and Europe.

Its therapeutic areas are deeply positioned in respiratory diseases, such as asthma, chronic obstructive pulmonary disease, and bronchiectasis, as well as nasal conditions, including allergic rhinitis and chronic sinusitis. The company is also strategically expanding into pulmonary fibrosis, pulmonary arterial hypertension, rare pulmonary infections, and central nervous system diseases, pioneering exploration into the novel frontier of precise "nose-to-brain" drug delivery.

Currently, CF PHARMTECH has established an extensively covered, multi-dimensional commercial network in China. Supported by a globally compliant manufacturing system and increasingly deepening international presence, the company is steadily progressing toward its goal of becoming a global innovative pharmaceutical enterprise.